Heron Therapeutics (NASDAQ:HRTX – Get Free Report) and Aspire Biopharma (NASDAQ:ASBP – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Heron Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 1 | 3 | 1 | 0 | 2.00 |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 500.60%. Given Heron Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Heron Therapeutics is more favorable than Aspire Biopharma.
Profitability
This table compares Heron Therapeutics and Aspire Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -22.52% | -293.02% | -10.00% |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
Valuation and Earnings
This table compares Heron Therapeutics and Aspire Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heron Therapeutics | $151.18 million | 0.42 | -$20.19 million | ($0.19) | -1.75 |
| Aspire Biopharma | $97,659.00 | 123.69 | -$24.48 million | ($69.62) | -0.12 |
Heron Therapeutics has higher revenue and earnings than Aspire Biopharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Heron Therapeutics beats Aspire Biopharma on 11 of the 14 factors compared between the two stocks.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
